Zimmer Biomet Holdings Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B), while ZIM Integrated Shipping Services Ltd trades at $29.96 (market cap $3.65B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 4.6× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays the higher dividend (20.16%). Which is the better fit depends on your goals — on Pluang, investors hold Zimmer Biomet Holdings Inc for 89 Days and ZIM Integrated Shipping Services Ltd for 27 Days on average.
| ZBH | ZIM | |
|---|---|---|
Market Cap | $16.95B | $3.65B |
Volume | 2,505,240 | 1,068,475 |
Sector | Health | Industrials |
52-Week High | $103.98 | $30.51 |
52-Week Low | $79.58 | $12.44 |
Typical Hold Time | 89 Days | 27 Days |
Enterprise Value | $24.02B | $7.32B |
Dividend Yield | 1.08% | 20.16% |
Signals from Pluang's Aura AI — not financial advice
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
ZIM trades at $29.99, near its 52-week high of $30.96, reflecting strong momentum. The stock shows a bullish technical trend with moving averages supporting upside, while oscillators are neutral. Fundamentally, Q2 2026 earnings beat expectations with EPS of $0.53 versus a forecasted loss, driven by higher freight rates and volumes. Revenue for 2026 is projected at $6.4B with a net income margin of 2.15%. The company faces a pivotal moment with Hapag-Lloyd's acquisition offer under Israeli government review.
The outlook is mixed: operational improvements and record transpacific rates offer upside, but merger uncertainty caps near-term gains. Risks include deal rejection, competitive pressures, and volatile shipping rates. Analysts are cautious, with 67% hold ratings, signaling wait-and-see sentiment amid the acquisition saga.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →